LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. Key accomplishments and highlights include: Bot
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with t
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
Total revenue of $10 million, compared to $46 million in Q2 2022 Total cumulative partnered program starts of 106, up 20% from Q2 2022 Net loss of $0.11 per share on a basic and diluted basis, compared to a net loss of $0.02 per share on a basic and d
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase
HOUSTON--(BUSINESS WIRE)--DXP Enterprises, Inc. (NASDAQ:DXPE), a leading products and service distributor that adds value and total cost savings solutions to MRO and OEM customers in virtually every industry, plans to issue a press release announcing its
Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS® (voclosporin) Conference call to be hosted today a
Revising full-year guidance to reflect factors impacting offshore potash sales through Canpotex and lower global potash prices than previously anticipated. Announcing strategic actions expected to reduce controllable costs and enhance free cash flow. All
- To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg - - Phase 2 topline efficacy data expected in Q3/Q4 2023 -TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (N
Revenues of $1.035 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $32 Million Adjusted EBITDA (non-GAAP)1 of $179 Million Revenues Grew 10% as Reported and 12% on a Constant Currency1 Basis Compared to the Second Quarter of 2022,
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.